The EntroGen NGS Targeted Hotspot Panel is a comprehensive assay that detects clinically relevant mutations in solid tumors using next-generation sequencing, compatible with fresh frozen and FFPE samples. It offers high sensitivity, low DNA input, and the ability to batch up to 12 samples in a single run, making it ideal for labs with limited sample volumes.

EntroGen’s BRCA Complete™ Expanded Panel is a comprehensive NGS solution that detects both germline and somatic mutations in genes like BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 with high sensitivity and specificity. Compatible with blood, fresh frozen, and FFPE samples, the panel reduces allele dropouts and off-target reads using a tiled amplicon PCR approach. It includes reagents for library preparation and user-friendly software for easy mutation identification, along with quality control assays to ensure high-quality data without repeat sequencing.

Certificate: ROU 

Supplier: Illumina 

For Mid and Low-throughput laboratories performing COVID-19 surveillance and identification of new variants

As a product of Panagene (Korea), the PANAMAX ™ 48 automatic extraction device works on the principle of using lysis and binding of samples by magnetic particles. Along with 3 samples kit ready-for-use for the process of extracting DNA/RNA/ccfDNA, this is the solution automatically 100%, just adding the sample to the correct specified wells, the […]

BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test

BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.

 The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.

The PANA RealTyper™ HPV Screening Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC

The PANA RealTyper™ STD Kit is an in vitro diagnostic reagent for genotyping of 13 pathogens involved in sexually transmitted infections (STI) from vaginal swab and urine.

The PANA RealTyper™ STD Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.

TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants